<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53586">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01831531</url>
  </required_header>
  <id_info>
    <org_study_id>ESO2013-01</org_study_id>
    <nct_id>NCT01831531</nct_id>
  </id_info>
  <brief_title>Study of S-1 in Combination With Radiotherapy in Esophageal Cancer</brief_title>
  <official_title>Phase II Study of S-1 in Combination With Radiotherapy in Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial aims to study the safety, the local control, and the overall survival of S-1
      combined with radiotherapy for patients with esophageal squamous cell carcinoma. 105
      patients will be recruited into this trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>1 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>1-yr local control rate</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>2-yr local control rate</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>3-yr local control rate</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>1-yr overall survival</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-yr overall survival</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-yr overall survival</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive chemoradiation with S-1.
Interventions:
Drug: S-1 Radiation: Radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>S-1 40 mg (BSA ≤ 1.6 m2) or 50 mg (BSA &gt;1.6 m2) p.o bid d1-28</description>
    <arm_group_label>S-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.</description>
    <arm_group_label>S-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Joined the study voluntarily and signed informed consent form;

          -  Age ＞75 or age 18-75 who are intolerant of or reject intravenous chemotherapy

          -  Both genders

          -  Esophageal squamous cell carcinoma confirmed by pathology

          -  Local advanced esophageal squamous cell carcinoma (T2-4N0-1M0-1a,TxN1M0-1a,TxNxM1a,
             AJCC 6th)

          -  No radiotherapy, chemotherapy or other treatments prior to enrollment

          -  PS ECOG 0-2

          -  Life expectancy of more than 3 months

          -  Hemoglobin（Hb）≥9 g/dL

          -  WBC≥3x109/L, Neutrophils (ANC )≥1.5x109/L

          -  platelet count (Pt) ≥100x 109/L

          -  Hepatic function: ALAT and ASAT &lt; 2.5 x ULN, TBIL&lt;1.5 x ULN

          -  Renal function: creatinine &lt; 1.5 x ULN

          -  No immuno-deficiency

          -  Use of an effective contraceptive for adults to prevent pregnancy.

        Exclusion Criteria:

          -  Complete esophageal obstruction

          -  Deep esophageal ulcer

          -  Esophageal perforation

          -  Haematemesis

          -  After surgery, exploratory thoracotomy, radiotherapy, chemotherapy, or targeting
             therapy

          -  Other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma
             in situ, who survived with no evidence disease for over 3 years

          -  Participation in other interventional clinical trials within 30 days

          -  Pregnant or breast-feeding women or people during the birth-period who refused to
             take contraceptives

          -  Drug addiction

          -  Alcoholism or AIDS

          -  Uncontrolled seizures or psychiatric diseases, loss of control over their own
             behavior

          -  Patient who has metastasis such as lung, liver metastasis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kuaile Zhao, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yun Chen, M.M.</last_name>
    <phone>8621-64175590</phone>
    <phone_ext>6726</phone_ext>
    <email>chenyun_qz@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Chen, M.M.</last_name>
      <phone>8621-64175590</phone>
      <phone_ext>6726</phone_ext>
      <email>chenyun_qz@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Kuaile Zhao, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yun Chen, M.M.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 13, 2013</lastchanged_date>
  <firstreceived_date>April 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Kuai Le Zhao, MD</investigator_full_name>
    <investigator_title>Professor of Radiation Oncology</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
